Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Is Adient (ADNT) a Great Value Stock Right Now?
Is Adient (ADNT) a Great Value Stock Right Now?

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always

Should Value Investors Buy Shinhan Financial Group Co (SHG) Stock?
Should Value Investors Buy Shinhan Financial Group Co (SHG) Stock?

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop

Is Sonic Automotive (SAH) Stock Outpacing Its Retail-Wholesale Peers This Year?
Is Sonic Automotive (SAH) Stock Outpacing Its Retail-Wholesale Peers This Year?

For those looking to find strong Retail-Wholesale stocks, it is prudent to search for companies in the group that are outperforming their peers. Sonic Automotive (SAH) is a stock that can certainly

Is Imperial Tobacco Group (IMBBY) Stock Outpacing Its Consumer Staples Peers This Year?
Is Imperial Tobacco Group (IMBBY) Stock Outpacing Its Consumer Staples Peers This Year?

The Consumer Staples group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Imperial Tobacco Group PLC (IMBBY) is a stock that can

Is Bank OZK (OZK) a Great Value Stock Right Now?
Is Bank OZK (OZK) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

Why Eversource Energy (ES) is a Top Value Stock for the Long-Term
Why Eversource Energy (ES) is a Top Value Stock for the Long-Term

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates

Badger Meter (BMI) Lags Q2 Earnings Estimates
Badger Meter (BMI) Lags Q2 Earnings Estimates

Badger Meter (BMI) came out with quarterly earnings of $1.17 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.12 per share a year ago. These

Here's Why Encompass Health (EHC) is a Strong Value Stock
Here's Why Encompass Health (EHC) is a Strong Value Stock

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Here's Why CDW (CDW) is a Strong Value Stock
Here's Why CDW (CDW) is a Strong Value Stock

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational, and oral orexin 2 receptor agonist, alixorexton (formerly ALKS 2680)

Halliburton Q2 Earnings Meet Estimates on International Growth
Halliburton Q2 Earnings Meet Estimates on International Growth

Halliburton Company HAL reported second-quarter 2025 adjusted net income per share of 55 cents, the same as the Zacks Consensus Estimate but below the year-ago quarter’s profit of 80 cents

IVZ's Q2 Earnings Lag as Expenses Rise, Higher AUM Boosts Revenues
IVZ's Q2 Earnings Lag as Expenses Rise, Higher AUM Boosts Revenues

Invesco’s IVZ second-quarter 2025 adjusted earnings of 36 cents per share lagged the Zacks Consensus Estimate of 40 cents. Moreover, the bottom line declined 16.3% from the prior-year quarter.The

Steris (STE) Loses 6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Steris (STE) Loses 6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Steris (STE) has been on a downward spiral lately with significant selling pressure. After declining 6% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in

Here's Why CVS Health (CVS) is Poised for a Turnaround After Losing 7.7% in 4 Weeks
Here's Why CVS Health (CVS) is Poised for a Turnaround After Losing 7.7% in 4 Weeks

CVS Health (CVS) has been on a downward spiral lately with significant selling pressure. After declining 7.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is

North American Construction (NOA) Loses 8.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
North American Construction (NOA) Loses 8.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

North American Construction (NOA) has been on a downward spiral lately with significant selling pressure. After declining 8.6% over the past four weeks, the stock looks well positioned for a trend

Applied Materials (AMAT) Recently Broke Out Above the 20-Day Moving Average
Applied Materials (AMAT) Recently Broke Out Above the 20-Day Moving Average

After reaching an important support level, Applied Materials (AMAT) could be a good stock pick from a technical perspective. AMAT surpassed resistance at the 20-day moving average, suggesting a

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny

Shares of Sarepta Therapeutics SRPT are declining in the pre-market hours today after the announcement that it will voluntarily and temporarily halt all U.S. shipments of Elevidys, effective at the

How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?

AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic and depression drug Vraylar. Over the years, the company has

Tenet (THC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Tenet (THC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Tenet Healthcare (THC) reported $5.27 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.3%. EPS of $4.02 for the same period compares to $2.31 a year

Valmont (VMI) Reports Q2 Earnings: What Key Metrics Have to Say
Valmont (VMI) Reports Q2 Earnings: What Key Metrics Have to Say

Valmont Industries (VMI) reported $1.05 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 1%. EPS of $4.88 for the same period compares to $4.76 a year

Northrop Grumman (NOC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Northrop Grumman (NOC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2025, Northrop Grumman (NOC) reported revenue of $10.35 billion, up 1.3% over the same period last year. EPS came in at $7.11, compared to $6.36 in the year-ago quarter.

Here's What Key Metrics Tell Us About Interpublic (IPG) Q2 Earnings
Here's What Key Metrics Tell Us About Interpublic (IPG) Q2 Earnings

For the quarter ended June 2025, Interpublic Group (IPG) reported revenue of $2.17 billion, down 6.6% over the same period last year. EPS came in at $0.75, compared to $0.61 in the year-ago quarter.

Compared to Estimates, Old National Bancorp (ONB) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Old National Bancorp (ONB) Q2 Earnings: A Look at Key Metrics

Old National Bancorp (ONB) reported $654.37 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 35.8%. EPS of $0.53 for the same period compares to $0.46 a

Compared to Estimates, MSCI (MSCI) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, MSCI (MSCI) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2025, MSCI (MSCI) reported revenue of $772.68 million, up 9.1% over the same period last year. EPS came in at $4.17, compared to $3.64 in the year-ago quarter.

The

Sherwin-Williams (SHW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Sherwin-Williams (SHW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sherwin-Williams (SHW) reported $6.31 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 0.7%. EPS of $3.38 for the same period compares to $3.70 a year